Innovation
Partnering
Areas of interest
Immunology

Partnering opportunities we are looking for:

  • Gastroenterology, Respiratory, Nephrology

    • Innate, Adaptive, Fibrosis, Tolerance and Tissue Regeneration Targets

Example partnerships

We are advancing innovative science and transformative medicines for people living with inflammatory and autoimmune diseases, including a portfolio of first in class programs and innovative development approaches across inflammatory bowel disease (IBD), respiratory, and rheumatological diseases.

Promedior

Acquisition to further develop and commercialise PRM-151, a first-in-class recombinant human pentraxin-2 molecule targeted at preventing and potentially reversing fibrosis, including IPF.

Jnana Therapeutics

Collaboration to develop small molecules against multiple key regulators of cellular metabolism SLC transporters for selected targets in immunology and neurology.

Enterprise Therapeutics

Acquisition to further develop the TMEM16A potentiator for the treatment of cystic fibrosis and potentially other severe respiratory diseases.

Your dedicated partnering leads in Immunology

Enza di Modugno
Head of Immunology & Infectious Diseases, Pharma Partnering
Jean-Eric Charoin
Search & Evaluation Lead Immunology & Infectious Diseases, Pharma Partnering

If you have an opportunity for collaboration or an interesting technology, or if you have an asset in one of our areas of interest, we would like to hear from you.
Contact our Pharma Partnering Team

Interested in partnering with us?

More Pharma partnering areas

 View all areas

Discover more